Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alkermes receives inhaled program termination notice from Eli Lilly
The termination will become effective in 90 days. The termination of the agreement also results in the termination of the Air Insulin supply agreement. Alkermes is evaluating the
The termination will become effective in 90 days. The termination of the agreement also results in the termination of the Air Insulin supply agreement. Alkermes is evaluating the
The acquisition consists of an initial cash payment of $24 million, guaranteed minimum future payments of $3.7 million and potential additional cash payments based upon the future operational
The objective of the study was to increase the proportion of patients that achieve therapeutic success at six months as compared to placebo over background therapy of maximal
Levoleucovorin is indicated after high-dose methotrexate therapy in patients with osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of
The American Association of Retired Persons or AARP contended that the prices charged to wholesalers and direct buyers was high but the burden was not felt due to
Rx&D, the Canadian research-based pharmaceutical industry association has welcomed the government’s investment plan unveiled in the federal budget on February 26, 2008. The Canadian government also intends to
The EAEPC contended that the Spanish medicines law of 2006, which allows pharmaceutical companies to adopt differential pricing depending on whether the product is going be sold domestically
The company, a spin-off from the University of Michigan, has received a total of $30 million over the past 18 months from Perseus, a private equity management firm.
The submission is based on the recently completed Phase II/III prospective, double-blind placebo-controlled International Multi- center Prospective Angioedema C1-Inhibitor Trial (IMPACT), the largest HAE trial ever, that studied
The transaction will bring together three medically meaningful therapies, Revlimid, Thalomid and Vidaza, treating patients worldwide. These products are expected to generate multiple global revenue streams for accelerated